Teva launches generic arthritis treatment


Pfizer's Celebrex has annual US sales of $2.56 billion.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced the launch of the first US Food and Drug Administration (FDA)-approved generic equivalent to Celebrex (Celecoxib) capsules in the US. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib capsules.

Teva Global Generic Medicines president and CEO Siggi Olafsson said, “Teva is pleased to be the first to launch generic Celebrex. The addition of Celecoxib capsules to our US generics portfolio is further evidence of Teva’s commitment to bring affordable treatment solutions to patients."

Celebrex (Celecoxib) capsules, marketed by Pfizer, had annual sales of about $2.56 billion in the US, according to IMS data as of October 2014. Celebrex treats pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain as well as hereditary polyps in the colon.

Published by Globes [online], Israel business news - - on December 10, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018